StreetInsider.com News Articles

Exagen publishes systematic review showing AVISE lupus test performance

Mon, 01 Jun 2026 09:01:17 -0400

Exagen Inc. (NASDAQ: XGN) announced the publication of a systematic review in Lupus Science & Medicine demonstrating the diagnostic performance of its AVISE Lupus algorithm across multiple patient populations.

The review analyzed biomarker data from 3,132 individuals across 14 academic medical centers in studies conducted between 2011 and 2025. According to the publication, the AVISE Lupus test identified 25% of systemic lupus erythematosus patients who were not detected by conventional serologic markers including anti-dsDNA, anti-Smith, and complements C3 and C4.

The study reported that AVISE Lupus demonstrated an area under the curve up to 0.90, specificity above 98%, and performed consistently across

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Mon, 01 Jun 2026 09:00:00 -0400

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers

Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis

Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation

CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the publication of a new systematic review demonstrating that the AVISE Lupus algorithm delivers markedly superior diagnostic accuracy and consistency across patient populations compared

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Mon, 01 Jun 2026 09:00:00 -0400

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers

Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis

Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Mon, 01 Jun 2026 09:00:00 -0400

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers

Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis

Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

Mon, 01 Jun 2026 09:00:00 -0400

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers

Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis

Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation

Form SCHEDULE 13G EXAGEN INC. Filed by: Parian Ultreia LP

Wed, 27 May 2026 12:33:00 -0400

si-local-file:///var/storage/secattach/20260527/26556225.html

Form SCHEDULE 13G EXAGEN INC. Filed by: Parian Ultreia LP

Wed, 27 May 2026 12:33:00 -0400

si-local-file:///var/storage/secattach/20260527/26556225.html

Form SCHEDULE 13G/A EXAGEN INC. Filed by: Chernett Jorey

Wed, 20 May 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260520/26529707.html

Form SCHEDULE 13G/A EXAGEN INC. Filed by: Chernett Jorey

Wed, 20 May 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260520/26529707.html

Form S-8 EXAGEN INC.

Tue, 12 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260512/26477519.html

Form S-8 EXAGEN INC.

Tue, 12 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260512/26477519.html

Exagen (XGN) PT Lowered to $8 at BTIG

Tue, 12 May 2026 06:09:22 -0400

(Updated - May 12, 2026 6:09 AM EDT)

BTIG analyst Mark Massaro lowered the price target on Exagen (NASDAQ: XGN) to $8.00 (from $9.00) while maintaining a Buy rating.

The analyst commented: "Exagen delivered a ~5% revenue beat in Q1 relative to our/Street estimates and turned in 12% revenue growth in the quarter, on the back of 10% volume growth as well as a pickup in ASPs. A highlight from the Q1 call was management calling out a +15% Y/Y increase in ordering clinicians, which largely hailed from its specialty rheumatology call point. We are encouraged to see XGN deliver 10% volume

Exagen (XGN) PT Lowered to $8 at BTIG

Tue, 12 May 2026 06:09:22 -0400

(Updated - May 12, 2026 6:09 AM EDT)

BTIG analyst Mark Massaro lowered the price target on Exagen (NASDAQ: XGN) to $8.00 (from $9.00) while maintaining a Buy rating.

Form 10-Q EXAGEN INC. For: Mar 31

Mon, 11 May 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260511/26466296.html

Form 10-Q EXAGEN INC. For: Mar 31

Mon, 11 May 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260511/26466296.html

Exagen Inc. (XGN) Tops Q1 EPS by 5c ; Offers Guidance

Mon, 11 May 2026 08:04:46 -0400

Exagen Inc. (NASDAQ: XGN) reported Q1 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $17.31 million versus the consensus estimate of $16.41 million.

GUIDANCE:

Exagen Inc. sees FY 2026 revenue of $70-73 million, versus the consensus of $71.27 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

Exagen Inc. (XGN) Tops Q1 EPS by 5c ; Offers Guidance

Mon, 11 May 2026 08:04:46 -0400

GUIDANCE:

Exagen Inc. sees FY 2026 revenue of $70-73 million, versus the consensus of $71.27 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.

Form 8-K EXAGEN INC. For: May 11

Mon, 11 May 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260511/26465477.html

Form 8-K EXAGEN INC. For: May 11

Mon, 11 May 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260511/26465477.html

Exagen Inc. Reports First Quarter 2026 Results

Mon, 11 May 2026 08:00:00 -0400

CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.

Three Months Ended March 31,

		Three Months Ended March 31,